Aragon Pharmaceuticals

Aragon Pharmaceuticals

Based: San Diego
Raised: $37.7 million
Investors: Aisling Capital, Column Group, OrbiMed Advisors, Topspin Partners, and an undisclosed investor.

The scoop: After San Diego-based Aragon Pharmaceuticals wrapped its early-stage work on their anti-androgen prostate cancer drug ARN-509 with some encouraging indications of its impact on tumors, the biotech married up with a nontraditional investor to round up Series C cash. A group called the Topspin Fund, headed by one-time hedge fund wiz Jim Simons, put up half of the cash, which should get the developer through the crucial proof-of-concept stage and on the way to a potential partnership deal. Aragon's lead drug has been compared often to MDV-3100 at Medivation, which in fact has filed suit against UCLA claiming that their IP deal should cover 509 as well. "The lawsuit alleges that ARN-509 is a close analog of MDV3100, and was invented in the same laboratory at the academic institution from which we licensed MDV3100," noted a spokesperson from Medivation recently.

Aragon Pharmaceuticals

Suggested Articles

Cour unveiled phase 2 data showing that its treatment cut levels of pro-inflammatory cytokines and protected the gut in patients with celiac disease.

Three years after Bayer and gene-editing biotech CRISPR Therapeutics joined forces to launch and run Casebia Therapeutics.

Fresh off Tilos Therapeutics’ $773 million sale to Merck, Barbara Fox is taking the helm of another Cambridge-based company: Rheos Medicines.